TMB-L
|
Melanoma
|
TMB-L
|
Melanoma
|
trametinib + dabrafenib + PDR001 Sensitive: B - Late Trials
|
trametinib + dabrafenib + PDR001 Sensitive: B - Late Trials
|
TMB-L
|
Follicular Lymphoma
|
TMB-L
|
Follicular Lymphoma
|
rituximab Sensitive: B - Late Trials
|
rituximab Sensitive: B - Late Trials
|
TMB-L
|
CRC
|
TMB-L
|
CRC
|
durvalumab + CP-675206 Sensitive: C3 – Early Trials
|
durvalumab + CP-675206 Sensitive: C3 – Early Trials
|
TMB-L
|
Adrenal Cortex Carcinoma
|
TMB-L
|
Adrenal Cortex Carcinoma
|
mitotane Sensitive: C3 – Early Trials
|
mitotane Sensitive: C3 – Early Trials
|
TMB-L
|
Malignant Pleural Mesothelioma
|
TMB-L
|
Malignant Pleural Mesothelioma
|
PD1 inhibitor Resistant: C3 – Early Trials
|
PD1 inhibitor Resistant: C3 – Early Trials
|
TMB-L
|
Malignant Pleural Mesothelioma
|
TMB-L
|
Malignant Pleural Mesothelioma
|
PD-L1 inhibitor Resistant: C3 – Early Trials
|
PD-L1 inhibitor Resistant: C3 – Early Trials
|
TMB-L
|
GBM
|
TMB-L
|
GBM
|
PD1 inhibitor Sensitive: C3 – Early Trials
|
PD1 inhibitor Sensitive: C3 – Early Trials
|
TMB-L
|
NSCLC
|
TMB-L
|
NSCLC
|
atezolizumab Sensitive: C3 – Early Trials
|
atezolizumab Sensitive: C3 – Early Trials
|
TMB-L
|
NSCLC
|
TMB-L
|
NSCLC
|
durvalumab + CP-675206 Resistant: C3 – Early Trials
|
durvalumab + CP-675206 Resistant: C3 – Early Trials
|
TMB-L
|
Pancreatic Cancer
|
TMB-L
|
Pancreatic Cancer
|
nivolumab + BMS-986227 Sensitive: C3 – Early Trials
|
nivolumab + BMS-986227 Sensitive: C3 – Early Trials
|
TMB-L
|
Lung Cancer
|
TMB-L
|
Lung Cancer
|
Tyrosine kinase inhibitor Sensitive: C3 – Early Trials
|
Tyrosine kinase inhibitor Sensitive: C3 – Early Trials
|
TMB-L
|
Gastric Cancer
|
TMB-L
|
Gastric Cancer
|
Immunotherapy Resistant: C3 – Early Trials
|
Immunotherapy Resistant: C3 – Early Trials
|
TMB-L
|
Mast Cell Leukemia
|
TMB-L
|
Mast Cell Leukemia
|
T-lymphocyte cell therapy Sensitive: C3 – Early Trials
|
T-lymphocyte cell therapy Sensitive: C3 – Early Trials
|
TMB-L
|
Diffuse Large B Cell Lymphoma
|
TMB-L
|
Diffuse Large B Cell Lymphoma
|
T-lymphocyte cell therapy Sensitive: C3 – Early Trials
|
T-lymphocyte cell therapy Sensitive: C3 – Early Trials
|
TMB-L
|
NSCLC
|
TMB-L
|
NSCLC
|
nivolumab + HS-110 Sensitive: C3 – Early Trials
|
nivolumab + HS-110 Sensitive: C3 – Early Trials
|
TMB-L
|
Neuroendocrine Tumor
|
TMB-L
|
Neuroendocrine Tumor
|
toripalimab Sensitive: C3 – Early Trials
|
toripalimab Sensitive: C3 – Early Trials
|
TMB-L
|
CRC
|
TMB-L
|
CRC
|
bevacizumab Sensitive: C3 – Early Trials
|
bevacizumab Sensitive: C3 – Early Trials
|
TMB-L
|
NSCLC
|
TMB-L
|
NSCLC
|
palbociclib + avelumab + axitinib Sensitive: C3 – Early Trials
|
palbociclib + avelumab + axitinib Sensitive: C3 – Early Trials
|
TMB-L
|
Triple Negative Breast Cancer
|
TMB-L
|
Triple Negative Breast Cancer
|
durvalumab Sensitive: C3 – Early Trials
|
durvalumab Sensitive: C3 – Early Trials
|
TMB-L
|
Pancreatic Ductal Adenocarcinoma
|
TMB-L
|
Pancreatic Ductal Adenocarcinoma
|
trametinib + Torin1 Sensitive: D – Preclinical
|
trametinib + Torin1 Sensitive: D – Preclinical
|
TMB-L
|
Gastric Cancer
|
TMB-L
|
Gastric Cancer
|
olaparib Resistant: D – Preclinical
|
olaparib Resistant: D – Preclinical
|